WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
WEBINAR
How Clinical Trials Really Work: Roles, Responsibilities, and Rules
Clinical Trial System Map
April 22, 2026
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
This webinar builds from system map to accountability under pressure
1
Map the core parties in a trial and the duties each retains
2
Compare sponsor, investigator, site, CRO, and IRB-IEC obligations
3
Spot where oversight, delegation, and documentation fail in routine work
4
Apply GCP expectations to safety, data, and consent decisions
5
Use realistic cases to diagnose gaps and plan follow-up actions
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 1—Core Trial Actors And Their Primary Responsibilities
Actor
Primary role
Non-transferable accountability
Sponsor
Funds, designs, oversees trial
Overall trial quality and compliance
Investigator
Conducts trial at site
Participant safety, protocol conduct
Site team
Executes daily study tasks
Accurate records, qualified performance
CRO or vendors
Perform contracted functions
Tasks only, per sponsor oversight
IRB or IEC
Reviews ethics and consent
Independent protection of participants
Framed from ICH GCP principles and common regulatory expectations across modern trials.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 1—Clinical Trial Decisions, Evidence, And Oversight Loop
flowchart TD
A[Protocol and risk-based design] --> B[Site execution and participant interactions]
B --> C[Data and safety information captured]
C --> D[Monitoring review and issue detection]
D --> E[Sponsor oversight and corrective decisions]
E --> F[Updates to training processes and documentation]
F --> B
C --> G[Regulatory and ethics reporting]
G --> E
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Sponsors own the trial design, even when execution is outsourced
The sponsor decides what question the study will answer, how it will answer it, and what evidence will count as credible. Vendors can help build and run the study, but they do not inherit the sponsor's accountability for the design choices that shape participant risk and data reliability.
✓Owns protocol, amendments, and core scientific rationale
✓Sets key quality, safety, and operational expectations
✓Chooses vendors, but must define roles and interfaces clearly
✓Answers for design flaws that drive downstream noncompliance
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 2—Transferred Tasks vs Retained Sponsor Accountability
Area
May transfer task
Sponsor still accountable for
Study management
CRO coordination, timelines
Adequate oversight, quality, compliance
Safety operations
PV processing, case handling
Timely review, reporting, signal oversight
Data management
EDC build, cleaning, coding
Data integrity, fit-for-purpose controls
Monitoring
CRA visits, reports
Monitoring strategy and issue follow-up
TMF and records
Document filing support
Complete essential records, inspection readiness
Based on ICH GCP principles and common inspection expectations.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 2—Sponsor Oversight Flow Across Separate Vendors
flowchart TD
A[Sponsor governance plan] --> B[CRO study management]
A --> C[Data management vendor]
A --> D[Pharmacovigilance vendor]
B --> E[Issue and metric review]
C --> E
D --> E
E --> F[Escalation and CAPA]
F --> G[Sponsor documents decisions]
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
One weak interface can unravel an otherwise well-run study
A sponsor may have capable vendors and clean dashboards, yet still fail inspection if no one can explain who reviewed risks across the handoffs. This matters most when safety, data, and operations sit with separate partners and nobody closes the loop.
Biotech examplestudy management, DM, and PV split across vendors
Inspection questionwho integrated oversight across all three?
If the answer is fuzzy, accountability already is too
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Quality management and essential records are sponsor controls, not paperwork chores
Sponsors need a quality system that matches the trial's risks, complexity, and stage. That means identifying critical processes, setting review routines, tracking deviations and CAPAs, and maintaining essential records that can show what happened and why.
✓Use risk-based quality management, not generic checklists
✓Define how safety, protocol, and data issues get escalated
✓Maintain essential records that reconstruct study decisions
✓Review vendor performance with evidence, not optimism
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Investigators retain site accountability, even when tasks are delegated
Delegation helps a site function, but it does not move accountability away from the principal investigator. Regulators look for active oversight of participant safety, protocol conduct, and staff performance, not just a signed form in a binder.
✓The investigator remains responsible for participant safety at the site
✓Qualified staff may perform tasks, but oversight must be real and documented
✓Protocol compliance is a medical and operational duty, not a paperwork exercise
✓Sponsors and monitors can detect issues, but they do not replace investigator judgment
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 3—Site duties that can be delegated versus duties that still require investigator control
Responsibility area
May be delegated
Investigator must retain
Participant assessments
Yes, to qualified staff
Medical oversight, key decisions
Informed consent steps
Parts of process
Overall responsibility, adequacy
Source documentation
Yes
Accuracy oversight, review
IP handling tasks
Yes, per role
Control system, compliance
Safety follow-up
Yes, in workflow
Clinical evaluation, escalation
Based on ICH GCP principles and common FDA inspection themes.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 3—A workable oversight loop for investigator-led site conduct
flowchart TD
A[Protocol duties assigned] --> B[Confirm staff qualification]
B --> C[Document delegation and training]
C --> D[Staff perform study tasks]
D --> E[Investigator reviews safety and conduct]
E --> F{Issue or drift found?}
F -->|Yes| G[Retrain, document, escalate]
F -->|No| H[Continue oversight and review]
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
The informed consent process belongs to the investigator, not just the form
Consent is more than getting a signature before the first procedure. The investigator is responsible for ensuring the process is ethical, current, understandable, and appropriately documented, even when trained staff help conduct the discussion.
✓Consent must use the current IRB or IEC approved version
✓Participants need time, clarity, and a chance to ask questions
✓Re-consent may be required after amendments or new risk information
✓Weak consent documentation can trigger findings despite clean data
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Source data and investigational product control expose the site's true discipline
These are the places where routine habits either support compliance or quietly erode it. When source records are thin, training is stale, or investigational product control is loose, the site cannot easily defend what happened or why.
✓Source records should support eligibility, visits, dosing, and safety decisions
✓Entries must be attributable, legible, contemporaneous, and reviewable
✓IP receipt, storage, dispensing, and return need clear accountability
✓Incomplete retraining after amendments is a common and avoidable gap
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
CROs extend execution capacity, but sponsors still own oversight
A CRO can run major parts of trial execution, from study management to monitoring and vendor coordination. That does not move ultimate responsibility away from the sponsor, especially for quality, safety, and compliance.
✓CRO contracts transfer tasks, not sponsor accountability
✓Scope must define decisions, approvals, and escalation points
✓Oversight has to be active, documented, and risk-based
✓Inspection questions often target the sponsor-CRO interface
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 4—Common execution partners and their practical limits
Partner
Typical responsibilities
Limits and retained accountabilities
CRO
Study management, vendor coordination, reporting
Sponsor retains oversight and final accountability
CRA or monitor
Site visits, issue follow-up, verification
Cannot provide PI medical oversight
Central lab
Specialized testing, specimen logistics
Cannot resolve site consent failures
IRT or eCOA vendor
Randomization, drug supply, participant data tools
System errors still require sponsor oversight
Pharmacovigilance vendor
Case processing, narratives, reporting support
Sponsor still owns safety system oversight
Roles vary by contract, but regulatory expectations for retained accountability do not.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 4—Issue escalation across sponsor, CRO, site, and vendors
flowchart TD
A[Site or vendor detects issue] --> B[CRO or functional lead triages]
B --> C{Participant safety or data risk?}
C -->|Yes| D[Sponsor notified immediately]
C -->|No| E[Track and correct per plan]
D --> F[Assign actions, owner, due date]
E --> F
F --> G[Monitor effectiveness and closure]
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Monitoring is a control activity, not a substitute for site conduct
Monitors help the sponsor assess whether sites follow the protocol, protect participants, and generate credible data. They do not take over investigator duties, and they cannot fix weak site ownership by visiting more often.
✓CRAs verify, trend, and escalate, they do not run the site
✓Monitoring may be on-site, remote, or centralized
✓High enrollment can hide weak consent or safety follow-up
✓Findings matter only if they lead to timely correction
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Vendor-heavy studies fail at the seams, not usually inside one function
The hardest inspections are often about interfaces, not whether each vendor did its own narrow task. A biotech using separate vendors for study management, data management, and pharmacovigilance may have competent teams and still struggle to show coherent sponsor oversight.
✓List every handoff where data, decisions, or alerts change hands
✓Define who reconciles mismatches across systems and vendors
✓Use oversight meetings to review risks, trends, and overdue actions
✓Document why issues were escalated, accepted, or closed
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
IRB and IEC review covers risk, rights, and study changes
Ethics review is broader than approving a consent form. The committee evaluates whether the study is ethically acceptable, whether risks are reasonable, and whether participant protections match the protocol and population.
✓Review includes protocol, consent materials, recruitment, and participant-facing tools
✓The focus is risk minimization, fair selection, and protection of rights and welfare
✓Approval is conditional, it depends on the version reviewed and current study facts
✓Sites cannot treat ethics approval as a startup milestone that stays true forever
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Continuing review and amendments keep ethics oversight current
Common pressure points
✓Continuing review checks whether the study still supports a favorable risk-benefit balance
✓Revised consent documents must be version controlled and deployed at the right time
✓Amendments need review before use, unless a change is needed to remove immediate hazard
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
One missed re-consent can create a study-wide documentation problem
In the oncology example, a safety follow-up gap discovered 10 days later raises more than reporting questions. It can also expose whether participants were informed promptly about new risk information, whether the IRB or IEC was notified as required, and whether the consent process still matched actual study conditions.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Consent is a conversation, and re-consent has clear triggers
A signed form proves very little on its own. Regulators and inspectors look for evidence that the participant received understandable information, had a chance to ask questions, and agreed under conditions that were appropriate for the protocol and the person's circumstances.
✓Re-consent may be triggered by new risks, major amendments, or new alternatives to participation
✓Vulnerable populations need added safeguards, not just more signatures
✓The investigator retains responsibility even when trained staff support the process
✓Documentation should show who consented, when, which version, and under what circumstances
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
ALCOA-plus turns routine records into defensible evidence
Data quality rarely fails because someone wanted bad data. It fails when ordinary work leaves a weak trail, late entry, unclear correction, or missing context. ALCOA-plus gives teams a practical test for whether a record can support participant safety and credible results.
✓Attributable, legible, contemporaneous, original, accurate are the base
✓Plus complete, consistent, enduring, and available when needed
✓Corrections must preserve what changed, when, and by whom
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 5—ALCOA-plus in common study documents
Record type
What good looks like
Common failure
AE note
Date, grade, action, follow-up clear
Late entry, missing attribution
Consent note
Version, discussion, signatures match
Form signed, process undocumented
Dose record
Time, amount, hold reason recorded
Backfilled timing after visit
Lab review
Clinically reviewed, action documented
Result filed, no assessment
Deviation log
Issue, impact, action, closure linked
List kept, no CAPA logic
Use the principle against the actual record, not against memory of what happened.
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 5—SAE workflow with expected decision points
flowchart TD
A[Participant event identified] --> B[Site assesses seriousness and causality]
B --> C[Investigator ensures immediate medical oversight]
C --> D[Site reports SAE per protocol and regulation]
D --> E[Sponsor or PV vendor reviews case and expectedness]
E --> F{Reportable to regulators or ethics bodies?}
F -->|Yes| G[Expedited reporting and follow-up]
F -->|No| H[Document, track, and trend]
G --> I[Close loop with site and safety database]
H --> I[Close loop with site and safety database]
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
10 days late can turn a routine safety gap into a major finding
In the oncology example, the alarming fact is not the holiday weekend. It is that a participant was hospitalized, SAE follow-up was missed, and the gap surfaced only when the monitor found it 10 days later. Regulators often read that as a control failure, not a one-off inconvenience.
Timelines start when the site becomes aware, not when the monitor asks
Delayed follow-up weakens safety surveillance and sponsor reporting
The key question is who owned escalation coverage during the gap
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Deviations need impact assessment and CAPA, not just a log entry
A deviation log is only the starting point. Teams need to decide whether the event affected safety, rights, data credibility, or protocol compliance, then take proportionate corrective and preventive action. Inspection-ready habits come from closing loops while the details are still fresh.
✓Classify the deviation, then assess impact on participant and data
✓Separate immediate correction from preventive action
✓Link retraining, vendor fixes, or process changes to root cause
✓Keep essential records current so inspection readiness is daily, not theatrical
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Case triage gets clear when you ask three questions first
Who decides, who documents, who answers
✓Who had authority to decide the action at that moment
✓Who must answer to regulators if the process failed
✓Who had to document the event, rationale, and follow-up
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
The holiday-weekend SAE gap shows how support can mask accountability
This scenario looks operational, but it is really about delayed medical assessment, reporting discipline, and sponsor oversight. The monitor can surface the gap, but neither the monitor nor the CRO replaces investigator medical responsibility or sponsor safety accountability.
✓Investigator must ensure participant evaluation and timely site reporting
✓Site staff may support intake, routing, and document collection
✓Sponsor must assess reporting pathways, oversight, and escalation design
✓CRA verifies and escalates, but does not own site medical decisions
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Gray zones appear where vendors are busy but sponsor oversight is thin
The biotech with three separate vendors may have capable partners and still fail inspection if no one can explain how risks are overseen across handoffs. Regulators usually ask less about the org chart and more about how the sponsor knew issues were identified, escalated, and closed.
✓Vendor task lists do not equal sponsor oversight evidence
✓Safety, data, and protocol signals must connect across functions
✓Training gaps after amendments often expose weak change control
✓Ask what dashboard, meeting, or metric would have caught this sooner
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Thanks for watching
Next step: run one accountability review on an active or recent study
Map who decides, who supports, who documents, who escalates
Test one recent event, such as an SAE, deviation, or consent change
Review evidence, not assumptions: logs, training, oversight, CAPA
Leave with named owners, due dates, and a follow-up check